- Home
- PSFE vs IOVA Comparison
PSFE vs IOVA Comparison
Compare PSFE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- IOVA
- Stock Information
- Founded
- PSFE 1996
- IOVA 2007
- Country
- PSFE United Kingdom
- IOVA United States
- Employees
- PSFE N/A
- IOVA N/A
- Industry
- PSFE Business Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSFE Consumer Discretionary
- IOVA Health Care
- Exchange
- PSFE Nasdaq
- IOVA Nasdaq
- Market Cap
- PSFE 770.7M
- IOVA 771.4M
- IPO Year
- PSFE N/A
- IOVA N/A
- Fundamental
- Price
- PSFE $13.09
- IOVA $1.88
- Analyst Decision
- PSFE Sell
- IOVA Buy
- Analyst Count
- PSFE 4
- IOVA 10
- Target Price
- PSFE $17.38
- IOVA $12.22
- AVG Volume (30 Days)
- PSFE 424.0K
- IOVA 10.4M
- Earning Date
- PSFE 08-12-2025
- IOVA 08-07-2025
- Dividend Yield
- PSFE N/A
- IOVA N/A
- EPS Growth
- PSFE N/A
- IOVA N/A
- EPS
- PSFE N/A
- IOVA N/A
- Revenue
- PSFE $1,688,097,000.00
- IOVA $212,679,000.00
- Revenue This Year
- PSFE $2.88
- IOVA $86.62
- Revenue Next Year
- PSFE $6.73
- IOVA $69.95
- P/E Ratio
- PSFE N/A
- IOVA N/A
- Revenue Growth
- PSFE 3.50
- IOVA 11070.12
- 52 Week Low
- PSFE $11.60
- IOVA $1.64
- 52 Week High
- PSFE $26.25
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- PSFE 50.44
- IOVA 47.47
- Support Level
- PSFE $12.45
- IOVA $1.68
- Resistance Level
- PSFE $14.02
- IOVA $2.02
- Average True Range (ATR)
- PSFE 0.51
- IOVA 0.11
- MACD
- PSFE 0.13
- IOVA 0.03
- Stochastic Oscillator
- PSFE 55.36
- IOVA 61.42
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.